68 U.S. biotech / healthcare equity funds.
This list will be updated when there are notable fund closures or new launches. Updated as of 6/6/2025.
8,000+ readers get my weekly insights on public equity research.
Jeff Ubben didn’t leave Fidelity because he was bad at the job. He left because he was too good at it—and the money wouldn’t stop coming in. He kept trying to shrink the number of names in his portfolio, but the fund kept getting bigger and positions
Launches, Shutdowns, and Pivots
2025 was the year everything finally clicked. Audience grew in ways I didn’t expect, I learned more about building on the internet than any other year of my life, and three products have product-market fit. I am grateful for your support. Here’s what worked, what didn’t, and
If you have spent your whole career in public equity, whether on the sell side, at a hedge fund, a mutual fund or a family office, it feels natural to think going corporate should be easy. You know business models. You have built countless forecasts. You have talked to management